Nuvalent (NUVL) Change in Accured Expenses (2020 - 2026)
Nuvalent's (NUVL) quarterly Change in Accured Expenses came in at -$2.1 million in Q1 2026, down 471.85% YoY from $573618.6 in Q1 2025, and up 65.79% on a QoQ basis from -$6.2 million in Q4 2025.
Analysis
Nuvalent (NUVL) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Change in Accured Expenses data on file, last reported at -$2.1 million in Q1 2026.
- Quarterly Change in Accured Expenses fell 471.85% year-over-year to -$2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.7 million (down 66.02% YoY) and the FY2025 annual result came in at $11.5 million, down 57.34% from the prior year.
- Change in Accured Expenses climbed to -$2.1 million in Q1 2026, from -$6.2 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $13.7 million in Q4 2024 to a low of -$6.2 million in Q4 2025.
- A 5-year average of $3.0 million and a median of $2.5 million in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses jumped 5382.35% — and 2026, when it plunged 471.85%.
- Tracing NUVL's Change in Accured Expenses over 5 years: stood at $4.5 million in 2022, then decreased by 14.03% to $3.8 million in 2023, then surged by 257.18% to $13.7 million in 2024, then tumbled by 145.35% to -$6.2 million in 2025, then jumped by 65.79% to -$2.1 million in 2026.
- The last three Change in Accured Expenses figures came in at -$2.1 million (Q1 2026), -$6.2 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - | -2.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -2.13 Mn |
| Dec 31, 2025 | -6.24 Mn |
| Sep 30, 2025 | 5.23 Mn |
| Jun 30, 2025 | 12.84 Mn |
| Mar 31, 2025 | -373,000.00 |
| Dec 31, 2024 | 13.75 Mn |
| Sep 30, 2024 | 4.25 Mn |
| Jun 30, 2024 | 10.91 Mn |
| Mar 31, 2024 | -2.05 Mn |
| Dec 31, 2023 | 3.85 Mn |
| Sep 30, 2023 | 4.49 Mn |
| Jun 30, 2023 | 2.45 Mn |
| Mar 31, 2023 | -1.15 Mn |
| Dec 31, 2022 | 4.48 Mn |
| Sep 30, 2022 | -85,000.00 |
| Jun 30, 2022 | 2.33 Mn |
| Mar 31, 2022 | -1.24 Mn |
| Dec 31, 2021 | 2.17 Mn |
| Sep 30, 2021 | 1.29 Mn |
| Jun 30, 2021 | -117,000.00 |